NSCLC Liquid Biopsies and Exhaled VOC
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSt. Joseph's Healthcare Hamilton
About this trial
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for detecting mutations in extracted cell-free DNA in non-small cell lung cancer (NSCLC) patients, before and after surgery, and any recurrence within a 24-month postoperative follow-up period.
This is a pilot feasibility study, proposed as a 24-month prospective, single-center, non-interventional, observational trial with NSCLC-adenocarcinoma patients indicated for resection surgery with curative intent.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient must be at least 18 years of age
Patient must be able to provide consent
Patients undergoing surgical resection with curative intent for non-small cell lung cancer at St. Joseph's Healthcare Hamilton and Firestone Institute for Respiratory Health.
Disqualifiers
Resection done with non-curative intent or metastatic disease
other malignancies
Patients with previously treated malignancy less than 5 years prior to current resection (not including skin cancer).
Trial population
Patients undergoing surgical resection with curative intent for NSCLC, adenocarcinoma subtype at St. Joseph's Healthcare Hamilton and the Firestone Institute of Respiratory Health , above 18 years, able to provide consent
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Recruitment rate
the proportion of eligible participants recruited (threshold \>75%)
Time frame
December 20252
Data completion rate
proportion of samples that are usable (threshold \>80%)
Time frame
December 20253
Safety, adverse events
any adverse events (threshold \<10%)
Time frame
December 2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov